EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Incretin mimetics for weight loss forgive nonadherence

Anıl Cengiz iD, Calvin C Wu iD, Sean D Lawley iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16438 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Anıl Cengiz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mathematics, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Incretins, Weight Loss, Glucagon-Like Peptides, Medication Adherence. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

GLP‐1 and GIP‐GLP‐1 agonists have emerged as potent weight‐loss medications. These incretin mimetics often have low patient adherence, and as with any medication, clinically meaningful efficacy requires adequate adherence. But what constitutes “adequate” adherence for incretin mimetics? The purpose of this paper is to address this question. Materials and Methods We use mathematical modelling and stochastic simulation to investigate the weight loss efficacy of incretin mimetics under imperfect adherence. We use validated pharmacokinetic and pharmacodynamic models of semaglutide and tirzepatide and assume that simulated patients randomly miss doses.

Results

We find that semaglutide and tirzepatide forgive nonadherence, meaning that strong weight loss efficacy persists despite missed doses. For example, taking 80% of the prescribed doses yields around 90% of the weight loss achieved under perfect adherence. Taking only 50% of the prescribed doses yields nearly 70% of the weight loss of perfect adherence. Furthermore, such nonadherence causes only small fluctuations in body weight, assuming that patients do not typically miss more than several consecutive doses.

Conclusion

Incretin mimetics are powerful tools for combating obesity, perhaps even if patients can consistently take only half of their prescribed doses. The common assumption that significant weight loss requires at least 80% adherence needs revision.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IncretinsWeight LossGlucagon-Like PeptidesMedication AdherenceObesityAnti-Obesity AgentsHumansTirzepatideGastric Inhibitory PolypeptideModels, TheoreticalGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GIPGLP‐1pharmacodynamicspharmacokineticssemaglutide

Substanzen

IncretinsGlucagon-Like PeptidesTirzepatideGastric Inhibitory PolypeptideAnti-Obesity AgentsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Mathematics, University of Utah, Salt Lake City, Utah, USA.
  • Tono Health, Brooklyn, New York, USA.

ORCID-Profile: Anıl Cengiz, Calvin C Wu, Sean D Lawley

Förderung

  • National Science Foundation

Zitieren

APA

Cengiz, A., Wu, C. C., & Lawley, S. D. (2025). Incretin mimetics for weight loss forgive nonadherence. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16438

Vancouver

Cengiz A, Wu CC, Lawley SD. Incretin mimetics for weight loss forgive nonadherence. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16438

BibTeX
@article{Cengiz2025,
  author = {Cengiz, Anıl and Wu, Calvin C and Lawley, Sean D},
  title = {Incretin mimetics for weight loss forgive nonadherence},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16438}
}
Kostenlos starten →